<DOC>
	<DOC>NCT00004814</DOC>
	<brief_summary>OBJECTIVES: I. Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.</brief_summary>
	<brief_title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution. One group receives copolymer 1, a mixture of synthetic polypeptides composed of 4 amino acids, subcutaneously each day for 2 years. The other group receives an injection of placebo daily for 2 years.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Clinically or laboratorysupported definite multiple sclerosis Neurologically stable for at least 30 days prior to entry Expanded Disability Status Scale score no greater than 5 At least 2 documented relapses within 2 years prior to entry Onset of first relapse at least 1 year prior to randomization Prior/Concurrent Therapy Biologic therapy: No prior copolymer 1 Immunosuppressive therapy: No prior cytotoxic immunosuppressives, i.e.: Azathioprine Cyclophosphamide Cyclosporine At least 30 days since corticosteroids Radiotherapy: No prior lymphoid irradiation Patient Characteristics Not HIV or HTLVI seropositive No insulindependent diabetes mellitus No Lyme disease No requirement for aspirin or chronic nonsteroidal antiinflammatory drugs No pregnant or nursing women Adequate contraception required of fertile women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 1997</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>neurologic and psychiatric disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>